← Eichor
Condition: Her2 Neu Uterine Serous Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Neu Uterine Serous Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Phase 2 · 3 location(s) · Yale University · NCT02491099Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · 409 location(s) · National Cancer Institute (NCI) · NCT05256225Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 102 location(s) · DualityBio Inc. · NCT05150691
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.